175 related articles for article (PubMed ID: 32909325)
1. Combination therapy of brexpiprazole and aripiprazole for an adolescent patient with a first episode of schizophrenia: A case report.
Fujiyama H; Sugawara H; Kanno T; Kawahara K; Tanaka H; Fukuhara R; Boku S; Takebayashi M
Psychiatry Clin Neurosci; 2020 Dec; 74(12):666-667. PubMed ID: 32909325
[No Abstract] [Full Text] [Related]
2. Mechanism of action of brexpiprazole: comparison with aripiprazole.
Stahl SM
CNS Spectr; 2016 Feb; 21(1):1-6. PubMed ID: 26899451
[TBL] [Abstract][Full Text] [Related]
3. Treatment-resistant schizophrenia successfully maintained with brexpiprazole following abrupt withdrawal of clozapine due to neutropenia.
Okada T; Kumakura J; Yasuda M; Suda S
Asian J Psychiatr; 2020 Jan; 47():101836. PubMed ID: 31677398
[No Abstract] [Full Text] [Related]
4. Brexpiprazole: a new leaf on the partial dopamine agonist branch.
Hope J; Castle D; Keks NA
Australas Psychiatry; 2018 Feb; 26(1):92-94. PubMed ID: 29017334
[TBL] [Abstract][Full Text] [Related]
5. Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia.
Keks N; Hope J; Schwartz D; McLennan H; Copolov D; Meadows G
CNS Drugs; 2020 May; 34(5):473-507. PubMed ID: 32246399
[TBL] [Abstract][Full Text] [Related]
6. Brexpiprazole for the Treatment of Schizophrenia: A Review of this Novel Serotonin-Dopamine Activity Modulator.
McEvoy J; Citrome L
Clin Schizophr Relat Psychoses; 2016; 9(4):177-86. PubMed ID: 26757416
[TBL] [Abstract][Full Text] [Related]
7. The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study.
Citrome L; Ota A; Nagamizu K; Perry P; Weiller E; Baker RA
Int Clin Psychopharmacol; 2016 Jul; 31(4):192-201. PubMed ID: 26963842
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Brexpiprazole as Adjunctive Treatment in Major Depressive Disorder With Irritability: Post Hoc Analysis of 2 Pivotal Clinical Studies.
Fava M; Weiller E; Zhang P; Weiss C
J Clin Psychopharmacol; 2017 Apr; 37(2):276-278. PubMed ID: 28195853
[No Abstract] [Full Text] [Related]
9. Successful Use of Brexpiprazole for Parkinson's Disease Psychosis Without Adverse Effects: A Case Report.
Sanagawa A; Shiraishi N; Sekiguchi F; Akechi T; Kimura K
J Clin Psychopharmacol; 2019; 39(6):685-687. PubMed ID: 31688389
[No Abstract] [Full Text] [Related]
10. The preclinical discovery and development of brexpiprazole for the treatment of major depressive disorder.
Aftab A; Gao K
Expert Opin Drug Discov; 2017 Oct; 12(10):1067-1081. PubMed ID: 28718334
[TBL] [Abstract][Full Text] [Related]
11. A randomised, placebo-controlled 24-week study evaluating adjunctive brexpiprazole in patients with major depressive disorder.
Bauer M; Hefting N; Lindsten A; Josiassen MK; Hobart M
Acta Neuropsychiatr; 2019 Feb; 31(1):27-35. PubMed ID: 30223911
[TBL] [Abstract][Full Text] [Related]
12. A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia.
Forbes A; Hobart M; Ouyang J; Shi L; Pfister S; Hakala M
Int J Neuropsychopharmacol; 2018 May; 21(5):433-441. PubMed ID: 29415258
[TBL] [Abstract][Full Text] [Related]
13. [Preclinical pharmacological profiles and clinical efficacy of the novel antipsychotic drug brexpiprazole (REXULTI
Suzuki M; Niidome K; Maeda K; Kikuchi T; Usami T; Futamura T
Nihon Yakurigaku Zasshi; 2019; 154(5):275-287. PubMed ID: 31735758
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: A 52-week, open-label study.
Ishigooka J; Iwashita S; Tadori Y
Psychiatry Clin Neurosci; 2018 Jun; 72(6):445-453. PubMed ID: 29582518
[TBL] [Abstract][Full Text] [Related]
15. Brexpiprazole: A Review in Schizophrenia.
Frampton JE
Drugs; 2019 Feb; 79(2):189-200. PubMed ID: 30671869
[TBL] [Abstract][Full Text] [Related]
16. Brexpiprazole as Adjunctive Treatment for Major Depressive Disorder Following Treatment Failure With at Least One Antidepressant in the Current Episode: a Systematic Review and Meta-Analysis.
Kishi T; Sakuma K; Nomura I; Matsuda Y; Mishima K; Iwata N
Int J Neuropsychopharmacol; 2019 Nov; 22(11):698-709. PubMed ID: 31350882
[TBL] [Abstract][Full Text] [Related]
17. Adjunctive Brexpiprazole in Patients With Major Depressive Disorder and Irritability: An Exploratory Study.
Fava M; Ménard F; Davidsen CK; Baker RA
J Clin Psychiatry; 2016 Dec; 77(12):1695-1701. PubMed ID: 27379823
[TBL] [Abstract][Full Text] [Related]
18. Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin-dopamine activity modulator: a role for serotonin 5-HT1A and 5-HT2A receptors.
Ishima T; Futamura T; Ohgi Y; Yoshimi N; Kikuchi T; Hashimoto K
Eur Neuropsychopharmacol; 2015 Apr; 25(4):505-11. PubMed ID: 25687838
[TBL] [Abstract][Full Text] [Related]
19. Comparative Efficacy of Dopamine Partial Agonists by Doses for Treatment-Resistant Depression: A Systematic Review and Dose-Response Model-Based Network Meta-analysis.
Terao I; Kodama W
J Clin Psychopharmacol; 2024 Jul-Aug 01; 44(4):413-417. PubMed ID: 38639435
[TBL] [Abstract][Full Text] [Related]
20. Brexpiprazole: A Review in Schizophrenia.
Garnock-Jones KP
CNS Drugs; 2016 Apr; 30(4):335-42. PubMed ID: 27023789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
